Elevated Levels of Plasma Phenylalanine in Schizophrenia: A Guanosine Triphosphate Cyclohydrolase-1 Metabolic Pathway Abnormality?

Files

pone.0085945.pdf (175.71 KB)

Links to Files

https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0085945

Permanent Link

https://doi.org/10.1371/journal.pone.0085945
 http://hdl.handle.net/11603/21002

Collections

UMBC Psychology Department
UMBC Faculty Collection

Author/Creator

Author/Creator ORCID

Date

2014-01-21

Type of Work

journal articles
Text

Department

Program

Citation of Original Publication

Okusaga, Olaoluwa; Muravitskaja, Olesja; Fuchs, Dietmar; Ashraf, Ayesha; Hinman, Sarah; Giegling, Ina; Hartmann, Annette M.; Konte, Bettina; Friedl, Marion; Schiffman, Jason; Hong, Elliot; Reeves, Gloria; Groer, Maureen; Dantzer, Robert; Rujescu, Dan; Postolache, Teodor T.; Elevated Levels of Plasma Phenylalanine in Schizophrenia: A Guanosine Triphosphate Cyclohydrolase-1 Metabolic Pathway Abnormality?; PLoS One 9,1(2014); https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0085945

Rights

This item is likely protected under Title 17 of the U.S. Copyright Law. Unless on a Creative Commons license, for uses protected by Copyright Law, contact the copyright holder or the author.
Attribution 4.0 International (CC BY 4.0)

Subjects

Abstract

Background Phenylalanine and tyrosine are precursor amino acids required for the synthesis of dopamine, the main neurotransmitter implicated in the neurobiology of schizophrenia. Inflammation, increasingly implicated in schizophrenia, can impair the function of the enzyme Phenylalanine hydroxylase (PAH; which catalyzes the conversion of phenylalanine to tyrosine) and thus lead to elevated phenylalanine levels and reduced tyrosine levels. This study aimed to compare phenylalanine, tyrosine, and their ratio (a proxy for PAH function) in a relatively large sample of schizophrenia patients and healthy controls. Methods We measured non-fasting plasma phenylalanine and tyrosine in 950 schizophrenia patients and 1000 healthy controls. We carried out multivariate analyses to compare log transformed phenylalanine, tyrosine, and phenylalanine:tyrosine ratio between patients and controls. Results Compared to controls, schizophrenia patients had higher phenylalanine (p<0.0001) and phenylalanine: tyrosine ratio (p<0.0001) but tyrosine did not differ between the two groups (p = 0.596). Conclusions Elevated phenylalanine and phenylalanine:tyrosine ratio in the blood of schizophrenia patients have to be replicated in longitudinal studies. The results may relate to an abnormal PAH function in schizophrenia that could become a target for novel preventative and interventional approaches.